Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.
Yung Lyou, MD, PhD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the key takeaways from the phase 3 ENZAMET trial (NCT02446405) in metastatic prostate cancer.
ENZAMET examined whether the addition of an antiandrogen agent that was already approved for metastatic castration-resistant prostate cancer would be beneficial for use in the metastatic hormone-sensitive setting, as well, Lyou says. Ultimately, results from the trial indicated that androgen deprivation therapy (ADT) plus enzalutamide (Xtandi) yielded an overall survival (OS) benefit vs ADT plus nonsteroidal antiandrogens, such as bicalutamide (Casodex) or flutamide (Eulexin), Lyou explains. The estimated 3-year OS rates experienced with enzalutamide vs standard antiandrogen treatment were 80% and 72%, respectively, Lyou concludes.